


Antibody Engineering & Therapeutics

December 9-13, 2018
Manchester Grand Hyatt
San Diego, CA



The Most Innovative Science Presented by Leading Industry and Academic Experts
The Largest Exhibition Devoted to Antibody Engineering
The Leading Forum to Partner with Global Antibody Innovators and Suppliers



Keynote Speakers Share Strategies to Accelerate Your Antibody Molecules



TCR SEQUENCING: TRANSFORMING THE DIAGNOSIS AND CARE OF CUTANEOUS T CELL LYMPHOMAS

Rachael A. Clark, M.D., Ph.D.

Shing-Yiu Yip and Cecilia M. Hepp Associate Professor of Dermatology, HARVARD MEDICAL SCHOOL



BIOINFORMATICS AND COMPUTATIONAL APPROACHES TO PROTEIN ENGINEERING

David Baker, Ph.D.

Professor of Biochemistry,
UNIVERSITY OF WASHINGTON



BENRALIZUMAB, A MONOCLONAL ANTIBODY ENGINEERED FOR ENHANCED NK-CELL MEDIATED EOSINOPHIL DEPLETION

Bahija Jallal, Ph.D.

President, MedImmune and Executive Vice President,
ASTRAZENECA



EXPLOITING THE DIVERSE FUNCTIONS OF FcRn TO GENERATE THERAPEUTICS

Sally Ward, Ph.D.

Professor, Department of Molecular and Cellular Medicine, TEXAS A&M UNIVERSITY HEALTH SCIENCE Center and Centre for Cancer Immunology,
UNIVERSITY OF SOUTHAMPTON

Register by July 13 and Save \$500 www.antibodyeng.com

KNect365
Life Sciences



900+

ANTIBODY SCIENTISTS AND EXECUTIVES

Fast-track your antibody research to the clinic and beyond by collaborating with leading pharma, biotech, academia and solution providers from North America, Asia and Europe.



135+

GLOBAL SPEAKER PRESENTATIONS

Expand your pipeline of antibody therapeutics by hearing case studies, new data and industry updates from experts working across the entire spectrum of antibody discovery and development.



125+

POSTERS

Stay at the forefront of antibody innovation by accessing cutting-edge and unpublished data from fellow attendees.



75+

EXHIBITORS

Accelerate your promising therapeutic towards commercial success by connecting with leading technology and service providers.

PRE-CONFERENCE TRAINING COURSE

Sunday, December 9, 2018, 9:00am-5:00pm

Introduction to Antibody Engineering

Instructor: David Bramhill, Ph.D., Bramhill Consulting, LLC and Research, Corporation Technologies

*Additional registration fee applies. See the pricing grid in this brochure or visit the website for more details

PRE-CONFERENCE WORKSHOPS

Sunday, December 9, 2018, 1:00pm-5:00pm

Workshop A: Next-generation Sequencing for Antibody Library Analysis and Monoclonal Discovery and Engineering

Workshop Moderators:

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland

Workshop B: Immuno-Engineering 101: An Introduction to the Immune System

Workshop Moderators:

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom

James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

*Additional registration fee applies. See the pricing grid in this brochure or visit the website for more details

MAIN CONFERENCE

Monday-Thursday, December 10-13, 2018

Novel Indications for Therapeutic Antibodies

Session Chair: James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

Targeting Eosinophils and Mast Cells with AK002: A Novel Treatment Approach

Christopher Bebbington, Ph.D., Chief Scientific Officer, Allakos, Inc.

Collagen Fibrillogenesis Inhibitory Antibody

Andrzej Fertala, Researcher, Thomas Jefferson University

GDF-15 Receptor

David Shen, Ph.D., SVP, Head of Biologics Research and CMC, NGM Biopharma

IL1RAP as a Therapeutic Target

Göran Forsberg, Ph.D., Chief Executive Officer, Cantargia AB, Sweden

LRP6 and Fibrosis

Andrew Mendelsohn, Scientist, Wntgen LLC

Antibody Developability

Session Chair: K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

In vitro Measures to Predict PK

Laura Lin, Ph.D., Director of Biophysics and Analytics, Global BioTherapeutic Technologies, Pfizer, Inc.

Antibody Colloidal Stability

Peter Tessier, Ph.D., Albert M. Mattocks Professor of Pharmaceutical Science, Chemical and Biological Engineering, University of Michigan

Biochemical Developability of the Clinical Antibody Landscape

Yingda Xu, Ph.D., Director, Protein Analytics, Adimab

Extensional Flow Induced mAb Aggregation

David Brockwell, Ph.D., Associate Professor, School of Molecular and Cellular Biology, University of Leeds, United Kingdom

Improving Biotherapeutic Development Through Structured Data Utilization

Randal Ketchum, Ph.D., Vice President of Molecular Design, Just Biotherapeutics

Host Cell Proteins in mAb Manufacturing

Kelvin Lee, Ph.D., Gore Professor of Chemical & Biomolecular Engineering, University of Delaware

Libraries, Display, Selection and Screening

Session Chair: Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Bispecific Target Discovery by High Throughput Functional Screening of Hundreds of Combinations of Different Target Pairs

Helene Finney, Ph.D., Director, Functional Screening, UCB, United Kingdom

Novel Techniques for Fab Library Generation and Antibody Hit Discovery Using Yeast Surface Display

Stefan Zielonka, Ph.D., Principal Scientist, Protein Engineering & Antibody Technologies, Merck KGaA/EMD Serono, Germany

Synthetic Antibody Repertoire Design and Generation in Mammalian Cells Using CRISPR-Cas9-mediated homology-directed Mutagenesis

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, Switzerland

High Throughput Platform for Batch Reformatting of scFvs to IgGs for Functional Screening

Ben Kemp, Scientist, Medimmune (Invited)

Interpreting Antibody Function on a Repertoire Scale

Brandon Dekosky, Ph.D., Assistant Professor, Pharmaceutical Chemistry and Chemical Engineering, The University of Kansas

Microbiome

Session Co-Chairs:

Bertrand Routy, M.D., Ph.D., Principal Scientist, CRCHUM and Assistant Professor of Hematology-Oncology, Department of Medicine, University of Montreal, *Canada*

Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and Sparring Biologics B.V., *The Netherlands*

Microbiome Therapeutics

Lorenzo Tibaldi, Ph.D., Project Leader - Drug Discovery, Enterome Bioscience, *France*

Microbiome & Checkpoint Therapy

Bertrand Routy, M.D., Ph.D., Assistant Professor Hemato-oncology CHUM, University of Montreal Hospital Center, *Canada*

Immunogenicity

Session Co-chairs:

Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech

Valerie Quarumby, Ph.D., Staff Scientist and Director, BioAnalytical Sciences, Genentech

Immunogenicity in Biotherapeutic Development

Valerie Quarumby, Ph.D., Staff Scientist and Director, BioAnalytical Sciences, Genentech

Approaches to Immune Response Mitigation - Use of Systemic and Targeted Approaches to Immune Suppression

Amy Rosenberg, Division Director, US FDA (*Invited*)

Emicizumab Case Study: A Risk Mitigation Practice of Immunogenicity and Its Clinical Relevance

Shuichi Chiba, Ph.D., Department Manager, Safety Assessment, Chugai Pharmaceutical Co. Ltd., *Japan*

Secukinumab Demonstrates Significantly Lower in vitro Immunogenicity Potential Compared to Ixekizumab and Other Therapeutic Antibodies

Frank Kolbinger, Ph.D., Executive Director, Novartis Pharma AG, *Switzerland*

Vatreptacog Case Study: Retrospective Use of in silico Analysis, T cell Assays and MAPPs to Troubleshoot Unwanted Immunogenicity

Kasper Lamberth, Ph.D., Principal Scientist, Screening & Bioassay Technology, Novo Nordisk A/S, *Denmark*

Mechanisms of Immune Attack: Clinical Stories

Session Co-chairs:

Louis M. Weiner, M.D., Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

Gregory Adams, Ph.D., Chief Scientific Officer, Eleven Biotherapeutics

Anti-cd47 Antibody in Clinical Trials

Chris Takimoto, M.D., Ph.D., Chief Medical Officer, Forty Seven, Inc. (*Invited*)

Vaccines and Antibodies in Infectious Disease

Session Co-chairs:

Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute

Paul W.H.I. Parren, Ph.D., Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center and Sparring Biologics B.V., *The Netherlands*

Imaging Complement by Phase-plate Cryo-electron Tomography from Initiation to Pore Formation

Thom Sharp, Ph.D., Assistant Professor, Leiden University Medical Center, *The Netherlands*

Novel Antibodies Targeting Malaria

Robert Sauerwein, M.D., Ph.D., Professor, Faculty of Medical Sciences, Radboud UMC, *The Netherlands*

CAR-T/T-cell Recruitment in Solid Tumors

Session Co-Chairs:

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, *United Kingdom*

Janine Schuurman, Ph.D., Vice President, Research, Genmab, *The Netherlands*

GD2-targeted CAR T Cells in Gliomas

Robbie Majzner, M.D., Instructor, Pediatrics - Hematology & Oncology, Stanford

Oncolytic Vaccines Encoding T cell Engagers: Tumor-targeted Delivery and Anti-tumor Synergy

Christine E. Engeland, M.D., Ph.D., Physician-Scientist, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), *Germany*

Selecting and Expanding a Patient's Own Autologous T cells Based on Cancer Cell Targets for Treatment (ACTolog)

Harpreet Singh, Ph.D., Managing Director, CSO and Co-Founder, Immatics Biotechnologies GmbH, *Germany*

Glypicans as CAR T-Cell Therapy Targets in Cancer

Mitchell Ho, Ph.D., Senior Investigator, Laboratory of Molecular Biology, NIH NCI

CAR-T in the Tumor Microenvironment

Senior Scientist TBA, Autolus, *United Kingdom*

Meeting Challenges for Antibody Therapies in the Tumor Microenvironment

Session Co-Chairs:

Janine Schuurman, Ph.D., Vice President, Research, Genmab, *The Netherlands*

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, *United Kingdom*

Preclinical Validation of a Site-specifically Conjugated, ROR1-specific Anthracycline-ADC with Potent Immune-stimulatory Functions

Roger R. Beerli, Ph.D., Chief Scientific Officer, NBE-Therapeutics AG, *Switzerland*

Immunotherapy with CD3 Bispecific Antibody in Immuno Competent Mouse Models

Thorbald van Hall, Ph.D., Associate Professor, Leiden University Medical Center, *The Netherlands*

Data and Learnings from JTX-2011 and Other Earlier Stage Projects

Emma Lees, Ph.D., Senior Vice President, Research, Jounce Therapeutics

Clonal Expansions of Lymphocytes in Immune Repertoires

Session Co-chairs:

Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, *Canada*

Nina Luning Prak, M.D., Ph.D., Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania

Engineering and Application of Therapeutic Antibodies for Neurodegenerative Diseases

Session Co-chairs:

Anne Messer, Ph.D., Professor of Biomedical Sciences, University at Albany and Principal Investigator, Neural Stem Cell Institute, Regenerative Research Foundation

Cynthia A. Lemere, Ph.D., Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School

James S. Huston, Ph.D., Chairman, The Antibody Society; Managing Member, Huston BioConsulting, LLC

Structural and Functional Analyses of 3 Anti-pyroglutamate-3 Abeta Antibodies as the Basis for Alzheimer's Immunotherapy

Stephan Schilling, Ph.D., Scientist, Probiobdrug

Antibody Transport Vehicle (ATV): A Novel Brain Delivery Platform

Mark Dennis, Ph.D., Fellow, Denali Therapeutics

Preclinical/Clinical Studies and Combination Therapy

Session Chair: Gregory Adams, Ph.D., Chief Scientific Officer, Sesen Bio

Preclinical Studies of Targeted Radionuclide Therapy and Radiosensitization Strategies for Cancer Therapy

Marika Nestor, Ph.D., Associate Professor and Head of Research Group, Immunology, Genetics and Pathology, Uppsala University, *Sweden*

Phase 3 Trial Results of an Anti-CD22 Immunotoxin for Hairy Cell Leukemia

Ira Pastan, Director, National Cancer Institute (*Invited*)

Preclinical Development of an Agonistic Antibody Targeting the OX001R/OX001L Immune Escape Mechanism

Haining Huang, Ph.D., Senior Director, Immuno Oncology, Oxford BioTherapeutics, *United Kingdom*

Cancer Therapy Revisited

H. Kaspar Binz, Ph.D., Vice President and Co-Founder, Molecular Partners AG, *Switzerland*

Preliminary Results of the Vicinium Phase 3 VISTA Study in Subjects with High Grade Non-Muscle Invasive Bladder Cancer

Gregory Adams, Ph.D., Chief Scientific Officer, Sesen Bio

Novel Methods to Interrogate Receptors as Targets

Session Chair: Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, *Switzerland*

Developments in CyTOF and Follow-up Strategies (e.g. Linking to Oligo Barcodes)

Garry P. Nolan, Ph.D., Rachford and Carlota A. Harris Professor, Department of Microbiology and Immunology, Stanford School of Medicine

Presentation Title TBA

Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, *Switzerland*

Emerging Approaches and Challenges in Targeting Protein-Protein Interactions

Rami Hannoush, Ph.D., Principal Scientist & Group Leader, Genentech

Decoding Ligand Receptor Interactions

Bernd Wollscheid, Head of Proteomics Platform, ETH Zurich, *Switzerland*

Additional Confirmed Speakers

Finding the Needle in the Haystack: Combining Next Generation Sequencing (NGS) and Immunoinformatics to Characterize and Screen Antibody Libraries

Khalil Mazouari, Ph.D., Immunoinformatics Consultant, AbnomX, *Belgium*

Paired Antibody Repertoire Sequencing and Screening by Surface Display

David Johnson, Ph.D., Founder and CEO, GigaGen

Antibody Discovery and Engineering by Analyzing Repertoire Sequence Space

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, ETH Zurich/Swiss Federal Institute of Technology, *Switzerland*

Clonify: Unseeded Antibody Lineage Assignment from Next-generation Sequencing Data

Bryan Briney, Ph.D., Assistant Professor, Immunology and Microbiology, The Scripps Research Institute

Scientific Briefings

Build Better Antibodies with Machine Learning and SynBio

Claes Gustafsson, Ph.D., Co-founder and Chief Commercial Officer, ATUM

An Integrated Approach To Managing Immunogenicity Risk And Optimum Protein Design

Emilee Knowlton, Ph.D., Immunology Sales Specialist, ProImmune, Inc.

Advances in Automated Microfluidic Capillary Electrophoresis for IgG Analysis, from Screening through QC, using PerkinElmer's IntelliChip™ Assays

James White, Ph.D., Senior Application Scientist, PerkinElmer

Computational Approaches for Optimizing the Developability of Biotherapeutics

Nels Thorsteinson, Scientific Services Manager, Biologics, Chemical Computing Group, *Canada*

A Computational Framework for Predicting Protein Liabilities & Improvement of Antibody Developability

Johannes Maier, Ph.D., Principal Scientist, Schrodinger

Speeding Discovery and Development with High-Throughput, High-Precision Characterization of Clonal Populations

Troy Lionberger, Ph.D., Senior Manager, Technology Development, Berkeley Lights

RESERVE YOUR EXHIBIT BOOTH OR SPONSORSHIP TODAY!

KNect365's Antibody Engineering and Antibody Therapeutics conference offers a unique opportunity to reach the pre-eminent researchers working in this important field of science from both the industry and academic sectors.

The 28th Antibody Engineering & Therapeutics conference (the longest running such event in the world) is dedicated to current developments in the basic science of this important field, and also tracks the clinical progress of antibody based drug products.

A Format Designed for Your Interactions with Conference Audience

- Two evening cocktail receptions in an exhibit/poster hall with more than 100 scientific posters
- Two luncheons in exhibit/poster hall
- Exhibit/poster hall networking time open during sessions
- Corporate suites for private meetings

Platinum Sponsor
Ligand

Gold Sponsor
carterra

Silver Sponsors

aldevron

ATUM

Session Sponsors

ABZENA
Enabling better biopharmaceuticals

aldevron

ATUM

BERKELEY LIGHTS

carterra

CHEMICAL COMPUTING GROUP

fusion antibodies
from genes to proteins to antibodies

geneious
biologics

HARBOUR BIOMED

isogenica

Ligand

MabPlex

MaxCyte

PALL FortéBio

PerkinElmer
For the Better

PROIMMUNE
www.proimmune.com

SCHRÖDINGER

SGIDNA
A Synthetic Genomics, Inc. Company

Registration Sponsor
Ligand

Lanyard Sponsor
MabPlex

Notepad & Pen Sponsor
OmniAb

Exhibitors

(as of June 5, 2018)

Abveris Antibody
Abzena
Acrobiosystems
Aldevron
Antibody Solutions
Aragen Bioscience
Atum
AvantGen
Avid Bioservices
Benchling
Berkeley Lights, Inc.
Bionova Scientific
BPS Bioscience
Carterra
Chemical Computing Group
Chempartner
Fusion Antibodies
Geneious Biologics
Genovis Inc.
Gyros Protein Technologies
Harbour BioMed
Icosagen Cell Factory
ImmunoPrecise Antibodies
IntelliCyt
KBI BioPharma
LakePharma
MabPlex
Maxcyte
ModiQuest Research
NanoCollect Biomedical
Novoprotein
Pall ForteBio
PerkinElmer
PhyNexus
Promega
ProZyme
Roche Custom Biotech
Sapidyne Instruments
Schrödinger
Sphere Fluidics Limited
Thermo Fisher Scientific
Thomson Instrument
TTP Labtech
Twist Bioscience

Exhibit and sponsorships are limited! To build your custom sponsorship package, contact:

(A-L) Aimee Croke, Aimee.Croke@KNect365.com, +1.857.504.6697


(M-Z) Kristin Skahan, Kristin.Skahan@KNect365.com, +1.857.504.6730

Main Conference (Monday – Thursday)	Register by July 13, 2018 SAVE \$500	Standard Rate	INDUSTRY ADD-ON OPTIONS
INDUSTRY RATES	\$2,199	\$2,699	Half Day Workshop (Sunday PM): \$499 Full Day Training Course (Sunday): \$899 Poster Presentation: \$125
INDUSTRY GROUP RATES	\$1,999 per person	\$2,499 per person	
Main Conference (Monday – Thursday)	Register by July 13, 2018 SAVE \$350	Standard Rate	ACADEMIC/GOVT ADD-ON OPTIONS
ACADEMIC/GOVT* RATES	\$749	\$1,099	Half Day Workshop (Sunday PM): \$299 Full Day Training Course (Sunday): \$599 Poster Presentation: \$0
ACADEMIC/GOVT* GROUP RATES	\$649 per person	\$999 per person	

*Academic/Government rates are extended to full-time employees of government, universities and university-affiliated hospitals only. To register for only a training course or symposia, please contact Leslie Wu at E-mail: lwu@knect365.com; Tel: +1 646-895-7434.

REGISTER A GROUP OF 4+ AND SAVE UP TO \$200/PERSON

Companies that register 4+ attendees are eligible to receive up to an additional \$200 savings per person off the current registration rate. Register your group today at the lowest rate by contacting Leslie Wu at E-mail: lwu@knect365.com; Tel: +1 646-895-7434



Present a Poster to Showcase Your Company's Latest Research

Highlight your company's exciting research by presenting a scientific poster, which will be displayed in the exhibit & poster hall during the event. You must be a registered attendee to present a poster. Poster fee is \$125 for industry attendees and free for academic/government attendees. The deadline to submit your poster is November 7, 2018.



Sponsorship/Exhibition Opportunities

Highlight your expertise directly to 800+ scientists and high level decision makers and influencers working across antibody engineering, antibody therapeutics and protein discovery and development by becoming an event sponsor or exhibitor. Contact Aimee Croke at aimee.croke@knect365.com or (857) 504-6697 for pricing and package details, or to see a sample attendee list from Antibody Engineering 2017. Reserve your spot early to ensure company placement in our printed brochure.



Venue Information:

Manchester Grand Hyatt San Diego

1 Market Place, San Diego, CA 92101

Phone: (888) 421-1442

Special Attendee Room Rate: \$235/night + tax

Please call the hotel directly at the number above or book online and reference "Antibody Engineering" to receive the reduced room rate. Special hotel rates are good through November 16, 2018 or until room block is sold-out.